SVB Securities Maintains Outperform on Castle Biosciences, Lowers Price Target to $35
Portfolio Pulse from Benzinga Newsdesk
SVB Securities analyst Puneet Souda maintains an Outperform rating on Castle Biosciences (NASDAQ:CSTL) but lowers the price target from $50 to $35.
June 05, 2023 | 1:57 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
SVB Securities maintains an Outperform rating on Castle Biosciences but lowers the price target from $50 to $35.
The news directly mentions Castle Biosciences (CSTL) and the lowered price target by SVB Securities. While the Outperform rating is maintained, the reduced price target may have a neutral impact on the stock price in the short term as it indicates a lower growth potential than previously expected.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100